Key result
Genetic variants and serum phosphate were identified as AS-specific risk factors distinct from CAD, with serum phosphate increasing AS risk (OR 1.20; 95% CI 1.11-1.31; P=1.27×10-5).
Observational (n=453,041)
Yes
Odds Ratio: 1.2 (95% CI 1.11–1.31)
p-value: p=1.27 × 10-5
This genomewide association study identifies distinct genetic risk loci and risk factors, such as serum phosphate, that are specific to aortic stenosis compared to coronary artery disease, providing novel targets for future research.
Importance: Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist. However, it is unknown which genetic and cardiovascular risk factors might be AS-specific and which could be shared between AS and CAD. Objective: To identify genetic risk loci and cardiovascular risk factors with AS-specific associations. Design, Setting, and Participants: This was a genomewide association study (GWAS) of AS adjusted for CAD with participants from the European Consortium for the Genetics of Aortic Stenosis (EGAS) (recruited 2000-2020), UK Biobank (recruited 2006-2010), Estonian Biobank (recruited 1997-2019), and FinnGen (recruited 1964-2019). EGAS participants were collected from 7 sites across Europe. All participants were of European ancestry, and information on comorbid CAD was available for all participants. Follow-up analyses with GWAS data on cardiovascular traits and tissue transcriptome data were also performed. Data were analyzed from October 2022 to July 2023. Exposures: Genetic variants. Main Outcomes and Measures: Cardiovascular traits associated with AS adjusted for CAD. Replication was performed in 2 independent AS GWAS cohorts. Results: A total of 18 792 participants with AS and 434 249 control participants were included in this GWAS adjusted for CAD. The analysis found 17 AS risk loci, including 5 loci with novel and independently replicated associations (RNF114A, AFAP1, PDGFRA, ADAMTS7, HAO1). Of all 17 associated loci, 11 were associated with risk specifically for AS and were not associated with CAD (ALPL, PALMD, PRRX1, RNF144A, MECOM, AFAP1, PDGFRA, IL6, TPCN2, NLRP6, HAO1). Concordantly, this study revealed only a moderate genetic correlation of 0.15 (SE, 0.05) between AS and CAD (P = 1.60 × 10-3). Mendelian randomization revealed that serum phosphate was an AS-specific risk factor that was absent in CAD (AS: odds ratio [OR], 1.20; 95% CI, 1.11-1.31; P = 1.27 × 10-5; CAD: OR, 0.97; 95% CI 0.94-1.00; P = .04). Mendelian randomization also found that blood pressure, body mass index, and cholesterol metabolism had substantially lesser associations with AS compared with CAD. Pathway and transcriptome enrichment analyses revealed biological processes and tissues relevant for AS development. Conclusions and Relevance: This GWAS adjusted for CAD found a distinct genetic risk profile for AS at the single-marker and polygenic level. These findings provide new targets for future AS research.
No takes yet. Share an insight, caveat, or question.
Trenkwalder et al. (2024) conducted an observational in Aortic stenosis and coronary artery disease (n=453,041). Genetic variants and serum phosphate vs. Control participants was evaluated on Cardiovascular traits associated with AS adjusted for CAD (OR 1.20, 95% CI 1.11-1.31, p=1.27 × 10-5). Genetic variants and serum phosphate were identified as AS-specific risk factors distinct from CAD, with serum phosphate increasing AS risk (OR 1.20; 95% CI 1.11-1.31; P=1.27×10-5).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: